{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:46:04Z","timestamp":1783183564153,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62272346"],"award-info":[{"award-number":["62272346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Comput Sci"],"DOI":"10.1038\/s43588-024-00748-8","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T10:02:44Z","timestamp":1734948164000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Leveraging pharmacovigilance data to predict population-scale toxicity profiles of checkpoint inhibitor immunotherapy"],"prefix":"10.1038","volume":"5","author":[{"given":"Dongxue","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-7195","authenticated-orcid":false,"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9987-9024","authenticated-orcid":false,"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"748_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"748_CR2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"key":"748_CR3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"748_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"748_CR5","doi-asserted-by":"publisher","unstructured":"Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J. & Han, L. Harnessing big data to characterize immune-related adverse events. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-021-00597-8 (2022).","DOI":"10.1038\/s41571-021-00597-8"},{"key":"748_CR6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"748_CR7","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. 44, D1075\u2013D1079 (2016).","journal-title":"Nucleic Acids Res."},{"key":"748_CR8","doi-asserted-by":"crossref","first-page":"125ra131","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra131 (2012).","journal-title":"Sci. Transl. Med."},{"key":"748_CR9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan, J., Azimi, N., Strand, V., Yarur, A. & Fridman, M. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010\u20132019. Drug Saf. 44, 889\u2013897 (2021).","journal-title":"Drug Saf."},{"key":"748_CR10","doi-asserted-by":"publisher","unstructured":"Arcuri, D., Kaouache, M., Lagace, F., Sasseville, D. & Litvinov, I. A case\u2013control pharmacovigilance study of TNF-alpha inhibitors and interleukin inhibitors on tuberculosis, candida, lymphoma and suicidality using the FAERS database (2014\u20132020). J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.041 (2023).","DOI":"10.1016\/j.jaad.2023.05.041"},{"key":"748_CR11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother. Cancer 7, 286 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"748_CR12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018).","journal-title":"Lancet Oncol."},{"key":"748_CR13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol. 74, 1667\u20131678 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"748_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 59, 101967 (2023).","journal-title":"EClinicalMedicine"},{"key":"748_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"748_CR16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/bib\/bbaa040","volume":"22","author":"CY Lee","year":"2021","unstructured":"Lee, C. Y. & Chen, Y. P. Prediction of drug adverse events using deep learning in pharmaceutical discovery. Brief. Bioinform. 22, 1884\u20131901 (2021).","journal-title":"Brief. Bioinform."},{"key":"748_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/bib\/bbz140","volume":"22","author":"DA Nguyen","year":"2021","unstructured":"Nguyen, D. A., Nguyen, C. H. & Mamitsuka, H. A survey on adverse drug reaction studies: data, tasks and machine learning methods. Brief. Bioinform. 22, 164\u2013177 (2021).","journal-title":"Brief. Bioinform."},{"key":"748_CR18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e17 (2017).","journal-title":"Cell"},{"key":"748_CR19","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra245 (2014).","journal-title":"Sci. Transl. Med."},{"key":"748_CR20","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283\u20132289 (2006).","journal-title":"J. Clin. Oncol."},{"key":"748_CR21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000099840","volume":"76","author":"G Balercia","year":"2007","unstructured":"Balercia, G. et al. Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother. Psychosom. 76, 134\u2013140 (2007).","journal-title":"Psychother. Psychosom."},{"key":"748_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-019-0583-3","volume":"7","author":"JD Schoenfeld","year":"2019","unstructured":"Schoenfeld, J. D. et al. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J. Immunother. Cancer 7, 112 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"748_CR23","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01718-3","volume":"18","author":"F Teng","year":"2020","unstructured":"Teng, F., Li, M. & Yu, J. Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med. 18, 275 (2020).","journal-title":"BMC Med."},{"key":"748_CR24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/10408398.2012.744738","volume":"56","author":"KE Davis","year":"2016","unstructured":"Davis, K. E., Prasad, C., Vijayagopal, P., Juma, S. & Imrhan, V. Advanced glycation end products, inflammation, and chronic metabolic diseases: links in a chain? Crit. Rev. Food Sci. Nutr. 56, 989\u2013998 (2016).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"748_CR25","first-page":"e535","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"Bozkurt, B. et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 134, e535\u2013e578 (2016).","journal-title":"Circulation"},{"key":"748_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7861\/clinmed.2018-0440","volume":"20","author":"K Agarwal","year":"2020","unstructured":"Agarwal, K., Yousaf, N. & Morganstein, D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clin. Med. 20, 163\u2013168 (2020).","journal-title":"Clin. Med."},{"key":"748_CR27","doi-asserted-by":"publisher","unstructured":"Kalfeist, L. et al. Impact of glucocorticoid use in oncology in the immunotherapy era. Cells https:\/\/doi.org\/10.3390\/cells11050770 (2022).","DOI":"10.3390\/cells11050770"},{"key":"748_CR28","doi-asserted-by":"publisher","unstructured":"Jing, Y. et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003779 (2022).","DOI":"10.1136\/jitc-2021-003779"},{"key":"748_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18305-y","volume":"11","author":"D Galeano","year":"2020","unstructured":"Galeano, D., Li, S., Gerstein, M. & Paccanaro, A. Predicting the frequencies of drug side effects. Nat. Commun. 11, 4575 (2020).","journal-title":"Nat. Commun."},{"key":"748_CR30","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"748_CR31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"748_CR32","volume":"12","author":"Z Khan","year":"2021","unstructured":"Khan, Z. et al. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat. Commun. 12, 3355 (2021).","journal-title":"Nat. Commun."},{"key":"748_CR33","doi-asserted-by":"publisher","unstructured":"Klumper, N. et al. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-002949 (2021).","DOI":"10.1136\/jitc-2021-002949"},{"key":"748_CR34","doi-asserted-by":"publisher","unstructured":"Celada, L. J. et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aar8356 (2018).","DOI":"10.1126\/scitranslmed.aar8356"},{"key":"748_CR35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","volume":"13","author":"CL Batlevi","year":"2016","unstructured":"Batlevi, C. L., Matsuki, E., Brentjens, R. J. & Younes, A. Novel immunotherapies in lymphoid malignancies. Nat. Rev. Clin. Oncol. 13, 25\u201340 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"748_CR36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/ehjci\/jeaa113","volume":"21","author":"H Wassif","year":"2020","unstructured":"Wassif, H., Hussain, M., Collier, P. H. & Moudgil, R. Immunotherapy-mediated valvulitis: a new cardiovascular immunotherapy-related adverse event. Eur. Heart J. Cardiovasc. Imaging 21, 1102 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"748_CR37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.14740\/cr838","volume":"10","author":"M Sharma","year":"2019","unstructured":"Sharma, M., Suero-Abreu, G. A. & Kim, B. A case of acute heart failure due to immune checkpoint blocker nivolumab. Cardiol. Res. 10, 120\u2013123 (2019).","journal-title":"Cardiol. Res."},{"key":"748_CR38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ophtha.2019.09.018","volume":"127","author":"JH Francis","year":"2020","unstructured":"Francis, J. H. et al. Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition: unmasking and masquerading. Ophthalmology 127, 240\u2013248 (2020).","journal-title":"Ophthalmology"},{"key":"748_CR39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s43588-021-00138-4","volume":"1","author":"X Zhang","year":"2021","unstructured":"Zhang, X., Sumathipala, M. & Zitnik, M. Population-scale identification of differential adverse events before and during a pandemic. Nat. Comput. Sci. 1, 666\u2013677 (2021).","journal-title":"Nat. Comput. Sci."},{"key":"748_CR40","doi-asserted-by":"publisher","unstructured":"Liu, X. et al. GraphCDR: a graph neural network method with contrastive learning for cancer drug response prediction. Brief. Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab457 (2022).","DOI":"10.1093\/bib\/bbab457"},{"key":"748_CR41","volume":"12","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade. Oncogenesis 12, 37 (2023).","journal-title":"Oncogenesis"},{"key":"748_CR42","doi-asserted-by":"publisher","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01698-2 (2022).","DOI":"10.1038\/s41591-022-01698-2"},{"key":"748_CR43","doi-asserted-by":"publisher","unstructured":"Duffy, \u00c1. et al. Tissue-specific genetic features inform prediction of drug side effects in clinical trials. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abb6242 (2020).","DOI":"10.1126\/sciadv.abb6242"},{"key":"748_CR44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","volume":"39","author":"S Seabroke","year":"2016","unstructured":"Seabroke, S. et al. Performance of stratified and subgrouped disproportionality analyses in spontaneous databases. Drug Saf. 39, 355\u2013364 (2016).","journal-title":"Drug Saf."},{"key":"748_CR45","doi-asserted-by":"publisher","unstructured":"Reynolds, K. L. et al. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-002896 (2021).","DOI":"10.1136\/jitc-2021-002896"},{"key":"748_CR46","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak, G. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform. 216, 574\u2013578 (2015).","journal-title":"Stud. Health Technol. Inform."},{"key":"748_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda, J. M. et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci. Data 3, 160026 (2016).","journal-title":"Sci. Data"},{"key":"748_CR48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.32614\/RJ-2017-063","volume":"9","author":"T Canida","year":"2017","unstructured":"Canida, T. & Ihrie, J. openEBGM: an R implementation of the Gamma-Poisson Shrinker data mining model. R J. 9, 499\u2013519 (2017).","journal-title":"R J."},{"key":"748_CR49","doi-asserted-by":"publisher","unstructured":"Liu, J., Xu, C., Yin, C., Wu, W. & Song, Y. K-core based temporal graph convolutional network for dynamic graphs. IEEE Trans. Knowl. Data Eng. https:\/\/doi.org\/10.1109\/tkde.2020.3033829 (2020).","DOI":"10.1109\/tkde.2020.3033829"},{"key":"748_CR50","doi-asserted-by":"publisher","unstructured":"Yan, D., Bao, S., Zhang, Z., Sun, J. & Zhou, M. Leveraging real-world pharmacovigilance data with deep learning to predict population-scale toxicity profiling of checkpoint inhibitor immunotherapy. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14058682 (2024).","DOI":"10.5281\/zenodo.14058682"}],"container-title":["Nature Computational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43588-024-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-024-00748-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-024-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:42:43Z","timestamp":1742960563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43588-024-00748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1038\/s43588-024-00748-8","relation":{},"ISSN":["2662-8457"],"issn-type":[{"value":"2662-8457","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}